Teclistamab

Introduction Teclistamab is an anticancer immunotherapy marketed under the brand name Tecvayli. Pharmacologically, teclistamab-cqyv is a bispecific B-cell maturation antigen-directed CD3 T-cell engager used in relapsed or refractory multiple myeloma. Multiple myeloma is a malignant plasma-cell disorder. In this disease, abnormal plasma cells accumulate in the bone marrow and produce monoclonal immunoglobulin or light chains. … Read more